Neuromonics, Inc. is a medical device company dedicated to helping people with its treatments for ringing in the ears, clinically known as tinnitus.
Neuromonics manufactures and distributes the only FDA-cleared, patented and clinically proven medical devices designed for long-term, significant relief of tinnitus. The company also has received regulatory approval from the Therapeutic Goods Administration (TGA) in Australia.
Beginning with the work of Paul Davis, Ph.D., inventor of the Neuromonics Tinnitus Treatment, and research and development since the early 1990s, Neuromonics has helped thousands of tinnitus sufferers around the world improve their quality of life and overcome the daily challenges associated with tinnitus.
The company’s global operations are located in Westminster, Colo., in the United States, and in Sydney, Australia.
Neuromonics and the military
Following active duty, many military members complain of ringing in the ears. Neuromonics has experienced great success in helping veterans obtain relief from their tinnitus.
Through research and awarded grants, Neuromonics has demonstrated effectiveness in its products and services. Each of Neuromonics products fit the Progressive Tinnitus Management protocol that the U.S. Department of Veterans Affairs and Department of Defense utilize.
Eula Adams, CEO: With nearly 40 years of experience in the financial accounting, financial services and technology industries, Adams has most recently served as president of Denver-based Xcore Corporation. Previously, Adams served as senior vice president of storage sales and services for Sun Microsystems, and as president and senior vice president of First Data Corporation, working in Denver. Within First Data, he held the positions of president of Merchant Services, president of Card Issuer Services and president of Teleservices. He also was chief operating officer of Western Union, later acquired by First Data. Earlier in his career, the new CEO spent 19 years with Deloitte, in the greater Atlanta area and in New York City.
Ronald E. West, Chairman: With more than 25 years of experience in the medical device industry, Ron West is president of Go West Inc., a management consulting firm servicing the medical device Industry. He also serves on the board of the Deafness Research Foundation.
Mike Quinn, Director: Quinn co-founded Innovation Capital in 1999, and serves as managing partner of the firm. His experience spans banking, high-technology plastics, environmental, electronics and medical device industries in North America, Europe and Australia. Quinn has advised and mentored numerous companies in operational, strategic and financial matters.
Brigitte Smith, Director: Smith co-founded GBS Ventures Partners in 1998 and serves as managing director of the firm. Brigitte has been investing and managing investments for GBS’s $450m of life science specialised venture capital funds since 1998. With 20 years’ experience in venture capital, business strategy and start-up company operations, she also serves on the board of GBS portfolio companies AirXpanders Inc., Endoluminal Sciences Pty Ltd., Proacta Inc., and Vivive Inc., and was the founding investor and chair of Pharmaxis Pty Ltd. She has held operating roles with early-stage technology based companies in the United States and Australia, and was at a strategic management consultant with Bain & Company.
Duane Knight, Chief Financial Officer/Chief Operating Officer: Duane brings a career background in financial management for both public and private companies, and specialty in the medical device manufacturing industry, to Neuromonics. He has served as partner with Trinity Capital Services and chief financial officer for Denver Biomedical, Inc., and owner of D.C. Knight & Company, Inc. Knight also has held the positions of treasurer and vice president of finance for Mallon Resources Corporation, accounting manager for both Snyder Oil Corporation and Walker Associates, and audit manager for Hein + Associates, LLP, and Taake and Wieland. He holds a Master of Business Administration degree from the University of Colorado, and Bachelor of Science degree in business administration from Colorado State University.
Curtis Amann, Vice President of Marketing and Sales: Amann has served as a territory sales manager and director of sales of Neuromonics before his promotion to vice president. Before that time, he was a territory manager for ArthroCcare ENT (Austin, Texas), working with surgical instruments for ear, nose and throat surgeons. He also worked as a sales specialist for Tyco Healthcare/Kendall (New Orleans), working with vascular therapy products. Amann has held the positions of assistant director of corporate sales and athletic director of marketing at Tulane University, and account development manager with MCI Communications in New Orleans. He holds Master of Business Administration and Bachelor of Arts degrees from Tulane University.
Kris Robinson, Sales Director – Asia Pacific region: Robinson, an audiologist, joined Neuromonics in 2010. Before that time, he served as partner of a private audiology practice specializing in tinnitus treatment options in Perth, Western Australia. He holds a Bachelor of Science degree from the University of Western Australia, and then completed his post-graduate diploma work in audiology at the University of Melbourne.
GBS Venture Partners is an Australian-based life science specialist venture capital firm with more than $400 million under management. With offices in Melbourne and Sydney, GBS has invested in more than 30 private and public companies. The firm invests in and helps build life science companies that involve Australasian operations or technology on both sides of the Pacific. GBS team members take active roles at the board level of their portfolio companies. Additionally, GBS brings a significant international network of corporate collaborators and investors to further the prospects of portfolio companies.
Innovation Capital (www.innovationcapital.net)
Innovation Capital is a leading Australian venture capitalist with offices in Australia and the United States. The firm is an early-stage, diversified fund manager, investing across both physical and life sciences. Innovation Capital invests in businesses based on innovative Australian technology and unique intellectual property that present global opportunities in the medical device, telecommunications, IT, engineering, clean tech and biotech sectors. Innovation Capital’s team comprises entrepreneurs and executives with exceptional track records in founding and building technology-driven businesses that have become leaders in their fields. The firm brings decades of real-world entrepreneurial experience to the active, hands-on support of its investee companies, helping manage risk, maximize investor returns and nurture the companies on their paths to becoming globally successful businesses.